People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Biotech / Pharma, Pharmaceuticals, Computers, Biotech, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TwinStrand Biosciences, Inc. | — | Biotech / Pharma | Series C | $85.0M | $132.2M | 2019 |
| Limerick Biopharma Inc | — | Pharmaceuticals | Series B | $52.8M | $16.3M | 2009 |
| Aggregate Knowledge Inc | — | Computers | Series A | $46.1M | $378.4M | 2009 |
| Cyrus Biotechnology, Inc. | — | Biotech | Series B | $37.4M | $5.2M | 2017 |
| Adapx Inc | — | Other | Series A | $36.7M | $28.3M | 2009 |
| Symform, Inc. | — | Other Technology | Series A | $16.2M | $5.5M | 2014 |
| Groove Biopharma Corp | — | Other Health Care | Series A | $8.4M | $90.8M | 2010 |
| Plectix Biosystems Inc | — | Computers | Series A | $6.9M | $229.8M | 2008 |
| Acylin Therapeutics, Inc. | — | Biotechnology | Seed | $4.0M | $88.8M | 2010 |
| Oncofactor Corp | — | Biotechnology | Seed | $3.1M | $44.4M | 2011 |
| XORI Corp | — | Biotechnology | Seed | $2.1M | $93.4M | 2009 |
Chad Waite at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Chad Waite on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thong Le | 4 | 12 |
| Carl Weissman | 4 | 8 |
| Lindsay Rayle | 4 | 7 |
| Steve Dow | 3 | 7 |
| David Schubert | 3 | 6 |
| Steven Gillis | 2 | 23 |
| Steve Gillis | 2 | 13 |
| Lee Babiss | 2 | 5 |
| Janis Naeve | 2 | 3 |
| Kristina Burow | 1 | 16 |
| Jason Smith | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Ashu Garg | 1 | 12 |
| Erik Anderson | 1 | 12 |
| Nilanjana Bhowmik | 1 | 10 |
| Paul Martino | 1 | 9 |
| Scott Minick | 1 | 7 |
| Eric Bell | 1 | 7 |
| Brian Atwood | 1 | 6 |
| FRED ESHELMAN | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.